Open Access<p>Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland</p>
Author(s) -
Robert V. Thomann,
Stefan Zechmann,
Nicola Alexander-David,
François R. Jornayvaz
Publication year - 2020
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s252667
Subject(s) - medicine , hypoglycemia , insulin glargine , cohort , insulin , clinical endpoint , incidence (geometry) , type 2 diabetes , diabetes mellitus , prospective cohort study , cohort study , insulin detemir , gastroenterology , endocrinology , randomized controlled trial , physics , optics
Insulin glargine 300 U/mL (Gla-300; Toujeo ® ) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.